c6c161fd-9f0a-4ad5-96ba-b9ce811348fc
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.520
- MYC_TARGETS_V1+0.500
- E2F_TARGETS+0.470
- PANCREAS_BETA_CELLS+0.450
- G2M_CHECKPOINT+0.440
- UNFOLDED_PROTEIN_RESPONSE+0.380
- OXIDATIVE_PHOSPHORYLATION+0.370
- MTORC1_SIGNALING+0.350
- CHOLESTEROL_HOMEOSTASIS+0.250
- TNFA_SIGNALING_VIA_NFKB+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.490
- ALLOGRAFT_REJECTION-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ANGIOGENESIS-0.440
- COMPLEMENT-0.380
- COAGULATION-0.350
- IL6_JAK_STAT3_SIGNALING-0.340
- MYOGENESIS-0.340
- UV_RESPONSE_DN-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6bc5d616-670c-4778-a769-d5b64fc51d8e | — | — | 0.906 |
| 2 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.867 |
| 3 | TCGA-94-8035-01A-11R-2247-07 | — | cohortSQ1 | 0.867 |
| 4 | TCGA-85-8354-01A-31R-2326-07 | — | cohortSQ2 | 0.860 |
| 5 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.857 |
| 6 | MDT-AP-0843 | Med | Medulloblastoma | 0.855 |
| 7 | SRR8518170 | — | E | 0.852 |
| 8 | SRR975602 | — | — | 0.852 |
| 9 | 20020032.TNBC | — | E | 0.850 |
| 10 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.450 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |